In the News
US FDA Grants Breakthrough Designation for Blood Test to Help Diagnose Inaccessible Brain Tumors
The liquid biopsy has been developed by Datar Cancer Genetics to help diagnose brain tumors where a conventional biopsy is not possible.
A prospective, blinded study by a research team at the Imperial College, London (part funded by BTRC) showed very high accuracy in detecting malignant brain tumors.
Datar Cancer Genetics now has three Breakthrough Designations granted by the USFDA, including liquid biopsies for breast and prostate cancer detection.